Role of iron in UPS impairment model of Parkinson's disease (Q38164879)

30 August 2017

title

Role of iron in UPS impairment model of Parkinson's disease (English)

1 reference

30 August 2017

1 reference

Weidong Le

1

1 reference

30 August 2017

publication date

1 January 2014

1 reference

Parkinsonism and Related Disorders

30 August 2017

published in

1 reference

30 August 2017

volume

20 Suppl 1

1 reference

30 August 2017

page(s)

S158-61

1 reference

Pathogenesis of Parkinson's disease

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

100 years of Lewy pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Iron dysregulation in movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Brain iron homeostasis and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Genetics of iron regulation and the possible role of iron in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Midbrain iron content in early Parkinson disease: a potential biomarker of disease status

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Lysosomes in iron metabolism, ageing and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Generation of ferric iron links oxidative stress to α-synuclein oligomer formation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Iron: a new target for pharmacological intervention in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Modeling Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Adaptive changes in autophagy after UPS impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970038-5

7 January 2021

10.1016/S1353-8020(13)70038-5

Identifiers

DOI

1 reference

30 August 2017

1 reference